Abstract:In this review we have surveyed recent investigations of early cellular events in pulmonary fibrosis both in animal models and in human diseases. Analysis of the interactions of the numerous cell types in the lung following injury is an almost overwhelmingly complex enterprise. In the animal models experimental design has a profound effect on results, making it difficult to compare studies when species, fibrogenic agent, dose, route of exposure, schedule of administration, time course, and analytical methods may not be equivalent. In human diseases we are rarely able to obtain data at precisely the same time point in the course of the disease even among patients in the same study, and possible confounding variables present are legion. Transcending these difficulties for the moment, can we draw any conclusions from our current knowledge of early cellular interactions in pulmonary fibrosis? What is striking is not that there are so many agents that can potentially induce pulmonary fibrosis, but that the lung has such capabilities for recovery. Although the major effector cells may all initially participate in damaging the lung and initiating fibrosis, there is evidence that they may also have the capacity to participate in subsequent repair. Macrophages may initially recruit fibroblasts and stimulate them to proliferate, only to suppress them subsequently. Macrophage production of prostaglandins can lead to suppression of macrophage, neutrophil and lymphocyte responses, thus attenuating tissue injury and the development of fibrosis. Neutrophils may initially release toxic metabolites and enzymes that damage parenchyma. However, there is evidence that they may later play a role in attenuating fibrosis, perhaps through collagenase secretion, or through as yet unknown mechanisms. Lymphocytes may initially participate in a number of damaging ways by secreting chemoattractants for other cells and participating in destructive autoimmune processes. However, there is evidence that subpopulations of T cells may dramatically shift during the course of fibrosis, leading to attenuation of the process. It may thus be useful to consider irreversible pulmonary fibrosis as the end result of a process in which the balance of normal injury/repair mechanisms is disrupted. There is clearly no single "fibrogenic event." Rather, there seem to be a number of places where disruption of balance/repair processes may begin. In diseases of unknown etiology such as sarcoidosis or IPF, loss of control may occur at the genetic level, leading to the destructive alveolitis that is the apparent precursor of fibrosis.(ABSTRACT TRUNCATED AT 400 WORDS)

Exploring the Interplay between Cellular Senescence, Immunity, and Fibrosing Interstitial Lung Diseases: Challenges and Opportunities

Cellular Senescence in Lung Fibrosis

Human senescent fibroblasts trigger progressive lung fibrosis in mice

Immune mechanisms in fibrotic interstitial lung disease

Current Challenges and Novel Therapeutic Perspectives

Emerging role of immune cells as drivers of pulmonary fibrosis

Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease

The role of immune response in the pathogenesis of idiopathic pulmonary fibrosis: far beyond the Th1/Th2 imbalance

Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management

Fibrosing interstitial lung diseases: knowns and unknowns

Progression of fibrosing interstitial lung disease

Causes of Pulmonary Fibrosis in the Elderly

Role of Immune Cells in the Initiation and Progression of Pulmonary Fibrosis

Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players

Lost in Translation: Endoplasmic Reticulum–Mitochondria Crosstalk in Idiopathic Pulmonary Fibrosis

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

Early cellular events in pulmonary fibrosis

Interstitial lung diseases: never forget to think about it in primary care

The dawn of precision medicine in fibrotic interstitial lung disease